Advances in Psychedelic Therapeutics: Multimodal Iboga Analogs, EEG-Guided Psilocybin Dosing, and Optimized Harmine–DMT Formulations
Anna C. Renner, Robert B. Kargbo
ACS Medicinal Chemistry Letters December 16, 2025 DOI: 10.1021/acsmedchemlett.5c00714 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin DMT Ibogaine |
| Keywords | Electroencephalography Hallucinogen Investigational drugs Pharmacology |
| Key findings | Simplified iboga analogs, real-time EEG biomarkers for psilocybin dosing, and standardized harmine-DMT ratios together form a coherent framework for safer, more clinically actionable psychedelic medicines. |
Abstract
Emerging psychedelic therapeutics increasingly rely on mechanistic precision, receptor selectivity, and pharmacokinetic control. Recent inventions introduce simplified iboga analogs with tunable polypharmacology, real-time EEG biomarkers that individualize psilocybin dosing, and standardized harmine-DMT ratios with high bioavailability. Together, these innovations form a coherent framework for safer, more reliable, and clinically actionable psychedelic medicines.